title: How we use WinRho in patients with idiopathic thrombocytopenic purpura.
abstract: Primary immune thrombocytopenia (ITP) is an autoimmune disease that affects children and adults. WinRho SDF is a D immune globulin product that is Food and Drug Administration approved for the treatment of ITP in D+ pediatric and adult patients. WinRho is a plasma-derived biologic product dispensed from blood banks. Transfusion medicine physicians serve as a resource to health care providers regarding blood component and derivative usage and, as such, should be familiar with the use of WinRho for ITP, including the dosage, administration, and contraindications. This report details the transfusion medicine consultation practice and guidelines at a tertiary care academic medical center for the usage of WinRho SDF in patients with ITP.
authors.affiliation: Transfusion Medicine and Cellular Therapy, Department of Pathology and Cell Biology, New York Presbyterian Hospital, New York, New York.
authors.forename: Brie A
authors.initials: BA
authors.lastname: Stotler
authors.affiliation: Transfusion Medicine and Cellular Therapy, Department of Pathology and Cell Biology, New York Presbyterian Hospital, New York, New York.
authors.forename: Joseph
authors.initials: J
authors.lastname: Schwartz
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D064826:Transfusion Medicine / Q000379:methods; D055815:Young Adult
chemical_list: D018029:Rho(D) Immune Globulin